Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer

Dr. Tripathy on the Management of HR+ Early-Stage Breast CancerПодробнее

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancerПодробнее

Dr. Tripathy Discusses Breast Cancer Gene ProfilingПодробнее

Dr. Tripathy on Genomically Guided Therapy in Breast CancerПодробнее

Prognostic and predictive potential of CXCL11 in endocrine resistance in breast cancerПодробнее

Dr. Tripathy on the Use of Tamoxifen in Hormone Receptor-Positive Breast CancersПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

Frontline Therapy in HR-Positive Breast CancerПодробнее

Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast CancerПодробнее

Dr. Tripathy Discusses Breast Cancer BiomarkersПодробнее

Frontline Therapy in Metastatic Breast CancerПодробнее

Dr. Tripathy on Augmenting the Benefit of Hormonal Therapy in Breast CancerПодробнее

FDA Approval of Ribociclib for Metastatic Breast CancerПодробнее

Dr. Tripathy Discusses Maintenance Therapy in Breast CancerПодробнее

Dr. Varella on the Results of MONALEESA-7 in HR+/HER2- Breast CancerПодробнее

Dr. Tripathy on 10 Versus 5 Years of Aromatase InhibitorsПодробнее

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast CancerПодробнее

Role of endocrine therapy in early-stage HR-positive breast cancerПодробнее

Copy of Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast CancerПодробнее